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Original repOrt
Anti-M is a frequently detected naturally occurring antibody that 
has been reported in various clinical settings and also in voluntary 
donors. We describe here the clinical and laboratory findings 
of 11 cases with anti-M detected at our center. This report is a 
retrospective study in which we reviewed our immunohematology 
laboratory records for cases involving anti-M. Both donor 
and patient data from a 28-month period (September 2014 to 
December 2016) were reviewed. During this period, 11 examples 
of anti-M were detected (8 patients, 1 voluntary whole blood donor, 
and 1 hematopoietic stem cell donor. Anti-M was also detected in 
one external quality assessment scheme sample received during 
this period. In conclusion, anti-M can be detected in various 
clinical settings. This antibody can be clinically significant; in 
the laboratory, it can present as a serologic problem such as an 
ABO group discrepancy or an incompatible crossmatch. After 
detection, management and course of action is determined 
by both the antibody characteristics and the clinical setting. 
Immunohematology 2017;33:165–169.
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The MNS blood group system was identified by Landsteiner 
and Levine in 1927.1 Many antibodies in this system may be 
naturally occurring. The most common of these is anti-M, first 
described by Wolff and Johnson in 1933.2
The MNS blood group system consists of 49 antigens, 
of which two allelic pairs (M/N and S/s) are polymorphic in 
most populations.3 M and N are located on glycophorin A 
glycoprotein. Glycophorin A is expressed on the surface of 
mature as well as developing erythrocytes.4 Makroo et al.5 
reported the following prevalence rates in a northern Indian 
blood donor population: 34.6 percent M+N–, 54.1 percent 
M+N+, and 11.3 percent M–N+. Because the M antigen is 
destroyed by routinely available proteolytic enzymes, anti-M 
does not react with enzyme-treated red blood cells (RBCs).6 
Anti-M is generally active below 37°C, with optimum activity 
at 4°C.6 Hence, these antibodies are generally ignored in 
transfusion practice, although they can interfere in ABO 
plasma grouping and cause an ABO group discrepancy. If 
the antibody is active at 37°C, then M–, compatible RBCs 
must be transfused.7 We report here anti-M cases with varied 
presentations detected in our laboratory.
Materials and Methods
This report is from a tertiary care hemato-oncology 
center in eastern India treating patients with hematologic 
malignancies and solid tumors (i.e., gynecologic, 
gastrointestinal, head and neck, and soft tissue tumors). 
Pretransfusion antibody detection testing and crossmatch 
is performed for all RBC requests. Hematopoietic stem cell 
transplantations are performed in patients with hematologic 
as well as nonhematologic disorders. The pretransplant 
evaluation includes ABO blood grouping, extended RBC 
phenotyping, antibody detection testing, direct antiglobulin 
test (DAT), and autocontrol in both donor and recipient. In 
addition, major and minor crossmatches are performed. ABO 
grouping is performed by a conventional tube technique (CTT) 
with anti-A, anti-B, and anti-D reagents (Immucor India, 
New Delhi, India), and plasma ABO testing is performed 
using in-house reagent RBCs (A, B, and O). A second anti-D 
reagent (Tulip Diagnostics, Goa, India) is also tested. Antibody 
detection testing and identification is performed by the 
column agglutination technique (CAT) (Biovue System; Ortho 
Clinical Diagnostics, Raritan, NJ) using anti-IgG glass bead 
cards and commercially available 3-cell panels (Surgiscreen; 
Ortho Clinical Diagnostics) and 11-cell panels (Resolve Panel 
A; Ortho Clinical Diagnostics). Whenever necessary, the same 
is repeated in neutral or reverse diluent cards at 4°C. DAT, 
autocontrol, and crossmatch are performed by CAT. Extended 
phenotyping is performed by CTT using commercially available 
monoclonal antisera from Ortho Clinical Diagnostics. Titer is 
performed by the double dilution method using double-dose 
M+ (M+N–) group O RBCs. Standard validated methods are 
used.8
Results
Over a period of 28 months (September 2014 to December 
2016), 11 cases of anti-M were detected, comprising eight 
patients, one donor, one hematopoietic stem cell transplant 
donor, and one external quality assessment scheme (EQAS) 
sample containing anti-M. The patient/donor ages ranged 
from 2.5 to 82 years. Patient diagnoses and clinical profiles of 
the cases are given in Table 1.
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Immunohematologic Features of Anti-M in Patients
An ABO blood group discrepancy was noted in six of the 
eight patients, where anti-M interfered in the reverse grouping 
as detected by an extra reaction with O reagent RBCs. In five 
of these patients, this discrepancy was resolved by repeating 
the reverse group with a 15-minute incubation at 37°C. In one 
patient, the discrepancy was resolved by using M– reagent 
RBCs in reverse grouping.
Specificity of the antibody was determined in seven 
patients by antibody detection testing and identification at 
37°C. In one patient, anti-M was detected at 4°C. A dosage 
effect of anti-M, showing stronger agglutination strength with 
double-dose M+ reagent RBCs, was observed in four patients.
Antibody detection testing using serum treated with 
0.01 M dithiothreitol (DTT) (Himedia Laboratories, Mumbai, 
India) was performed on samples from five patients. In all 
these patients, the agglutination strength decreased but did 
not disappear, suggesting the presence of both IgG and IgM 
components in the antibody. In two patients, DTT treatment of 
the serum could not be performed, and the antibody detection 
testing was not repeated by a prewarmed test. Hence, whether 
this finding was a false reaction at 37°C due to high affinity 
IgM anti-M or a reaction due to an IgG component of anti-M 
was not determined. 
Titration of the anti-M was performed in four cases and 
was <1 (no reaction in neat plasma) at 37°C in all these cases. 
Because the test was performed by CTT, it is possible that 
titration by CAT might have shown different results, since 
CAT is more sensitive.9 Phenotyping for M was performed on 
samples from all eight patients; seven were found to be M– 
and one was M+. Of the seven M– patients, six had no known 
history of blood transfusion; it thus appears that, in these 
patients, the anti-M was naturally occurring. In the seventh 
patient (who received RBC transfusion earlier [outside our 
hospital]), the anti-M could not be characterized as immune-
stimulated or naturally occurring because the donor of the 
transfused RBCs was unavailable for M antigen testing. One 
patient with anti-M (acute lymphoblastic leukemia [ALL] case) 
was phenotyped as M+ with a positive DAT and autocontrol. 
This was thus a case of autoanti-M. The immunohematologic 
profile of these patients is summarized in Table 2.











1 Whole blood 
donor
24/F O+ NA No
2 Stem cell 
donor
3/F B+ NA No
3 Patient 3/F O+ Pre B ALL Yes
4 Patient 2.5/F A+ Pre B ALL No
5 Patient 5/M O+ T ALL No




7 Patient 24/F O+ Carcinoma 
breast
No
8 Patient 66/M O+ Multiple 
myeloma
No




10 Patient 72/M A+ Seminoma 
testis
No
NA = not applicable; Pre B ALL = Precursor B cell acute lymphoblastic 
leukemia; T ALL = T cell acute lymphoblastic leukemia.
Table 2. Serologic profile of anti-M in patients
Case 
number Presentation DAT Class of antibody Thermal amplitude Titer Management
3 Antibody detection testing Positive IgM ± IgG 4°C, RT, and 37°C 4°C: 16
RT: 4
M– RBC transfusion
4 ABO group discrepancy Negative IgM + IgG 4°C, RT, and 37°C NP M– RBC transfusion
5 ABO group discrepancy Positive IgM + IgG 4°C, RT, and 37°C NP M– RBC transfusion
6 ABO group discrepancy Negative IgM + IgG 4°C, RT, and 37°C 4°C: 4 No transfusion
7 ABO group discrepancy Negative IgM ± IgG 4°C, RT, and 37°C NP M– RBC transfusion
8 Antibody detection testing Negative IgM + IgG 4°C, RT, and 37°C 4°C: 8 M– RBC transfusion
9 ABO group discrepancy Negative IgM + IgG 4°C, RT, and 37°C 4°C: 4 No transfusion
10 ABO group discrepancy Negative IgM 4°C, RT NP No transfusion
DAT = direct antiglobulin test; RT = room temperature; RBC = red blood cell; NP = not performed.
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Immunohematologic Features of Anti-M in Donors
Anti-M was found in one whole blood donor and one 
hematopoietic stem cell donor. In the whole blood donor, a 
blood group discrepancy was noted and was resolved when 
the reverse group was repeated with prewarmed serum. The 
anti-M was also detected at 4°C and not at 37°C, suggesting 
possibly only an IgM component. The donor’s RBCs tested as 
M–. 
In the stem cell donor, anti-M was detected during the pre-
transplant evaluation. Although both the donor and recipient 
were group B, D+, the minor crossmatch was incompatible. 
Antibody identification confirmed anti-M reactive at 37°C, 
showing a dosage effect. Presence of IgG along with IgM 
was confirmed by DTT treatment of the serum. The RBCs 
were phenotyped as M–. Neither this donor nor the whole 
blood donor had history of blood transfusion, suggesting 
that the anti-M in both donors was naturally occurring. The 
immunohematologic profile of these donors is summarized in 
Table 3.
EQAS Sample
During the study period, anti-M was identified in one 
EQAS sample. This antibody was detected at 37°C and showed 
dosage. The agglutination strength increased when the testing 
was repeated at 4°C. DTT treatment of the plasma or antibody 
titration studies could not be performed nor was a transfusion 
history supplied with the sample.
Clinical Outcome of Anti-M in Patients and Donors
Among the patients with anti-M, five patients required 
RBC transfusion. As in most of the cases, the IgG component 
was present along with IgM; hence, the anti-M was considered 
to be clinically significant, and these five patients received 
M– RBC units. The patient with ALL who had autoanti-M 
had clinical as well as laboratory features of hemolysis. The 
unconjugated bilirubin was increased at 1.5 mg/dL (normal 
0–1.1 mg/dL), total bilirubin was 1.8 mg/dL (normal 0.2–1.3 
mg/dL), reticulocyte count was 4% (normal 0.5–2.5%), and 
lactate dehydrogenase was 4039 U/L (normal 313–618 U/L). 
This patient received injection dexamethasone along with RBC 
transfusion and responded well, confirmed by an increase in 
hemoglobin increment from 4.5 to 9.4 g/dL.
The anti-M in the hematopoietic stem cell donor was 
detected during pretransplant evaluation. Incompatibility 
between donor’s plasma and patient’s RBCs was detected, and 
anti-M was then identified. Because the stem cell donor was 3 
years of age, a marrow harvest was undertaken. RBC loss in 
the stem cell donor required transfusion of 1 RBC unit during 
the harvest. Because the donor had anti-M, group-specific, 
M–, crossmatch-compatible RBCs were transfused. To further 
complicate the matter, the stem cell recipient was M+. Because 
the donor anti-M was clinically significant, the marrow 
harvest product was plasma-depleted before transfusion to 
reduce chances of a hemolytic transfusion reaction. Hence, 
once anti-M is detected, further management of the patient 
depends on the specific clinical setting.
The donor unit, which had anti-M in the plasma, was 
separated into RBCs, platelets, and plasma components. The 
plasma was sent for fractionation, platelet concentrate was 
transfused to an M– patient, and the RBC unit was transfused 
to an ABO group-specific patient.
Discussion
In patients, anti-M may be detected in various medical 
as well as surgical settings. Das et al.10 reported three cases 
of anti-M, all of which were detected during pre-transfusion 
testing before surgery. In the present study, anti-M was 
detected in our medical and surgical oncology patients at the 
time of blood grouping and antibody detection testing. Our 
population consisted of medical and surgical oncology patients.
Generally, anti-M is IgM in nature, optimally reactive below 
22°C, and most often causes a blood grouping discrepancy. 
It may also be detected incidentally during pretransfusion 
evaluation. If there is no known stimulating event (i.e., 
RBC transfusion, pregnancy, or other exposure to foreign 
RBCs), the antibodies are classified as naturally occurring. 
Autoanti-M has also been reported in the literature. Anti-M 
is more commonly observed in children.6 In the present study, 
however, there were only four individuals younger than 10 
Profile of anti-M
Table 3. Serologic profile of anti-M in donors
Case 
number Presentation DAT Class of antibody Thermal amplitude Titer Management
1 ABO group discrepancy NP IgM 4°C and RT NP NA
2 Minor crossmatch incompatible Negative IgM + IgG 4°C, RT, and 37°C NP M– RBC transfusion
DAT = direct antiglobulin test; NP = not performed; RT = room temperature; NA = not applicable; RBC = red blood cell.
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years of age (three patients and one stem cell donor). Mathur 
et al.11 described one case of anti-M in a voluntary blood donor 
where the antibody had a thermal amplitude of 22°C to 37°C 
but showed no reaction at 4°C. This finding is in contrast to 
our finding from the whole blood donor, where the anti-M was 
reactive at room temperature with optimum activity at 4°C. 
Sacher et al.12 described 17 cases of autoanti-M, of which four 
had symptoms of cold agglutinin disease, such as Raynaud’s 
phenomenon, livedo reticularis, and acrocyanosis, and two 
had mild hemolysis; the rest were asymptomatic despite 
having a significant titer of the autoanti-M.
Patients with anti-M have been described by Tandon 
et al.13 and Kaur et al.14 These antibodies were identified as IgM, 
causing ABO grouping discrepancy, with optimum reactivity 
below 37°C. Anti-M with both IgM and IgG components and 
wide thermal amplitude (4°C–37°C) were also described. 
Hence, those authors suggest that when evaluating for the IgG 
component of anti-M, strict prewarmed conditions must be 
maintained during antibody identification to avoid interference 
by high-affinity, high-titer IgM.
Anti-M, which is commonly IgM in nature, can cause 
complement activation. In 1991, Combs et al.15 described 
an autoanti-M causing hemolysis in vitro by activating 
complement in CTT at low-ionic strength.
Naturally occurring anti-M with only an IgG component 
has been reported very rarely.6 Anti-M shows a dosage effect, 
that is, it shows a stronger reaction with RBCs with double-
dose expression of M (M+N–) than with RBCs with single-
dose expression (M+N+). For this reason, the prevalence of 
naturally occurring anti-M in blood donors was shown to 
be 1 in 2500 when testing with M+N– RBCs and 1 in 5000 
when using M+N+ RBCs.7 In our series, a dosage phenomenon 
was noted in 6 of the 11 cases described. Anti-M has also 
demonstrated increased reactivity when tested with serum 
that has been adjusted to a pH of 6.5.3 Beattie and Zuelzer16 
described two anti-M examples that were identified after 
acidification of the serum.
Delayed hemolytic transfusion reaction is very rare 
because of alloanti-M. Sancho et al.17, Alperin et al.18, and 
Furlong and Monaghan19 reported cases of alloanti-M that 
were undetectable during pretransfusion evaluation but were 
subsequently detected 5–15 days posttransfusion during 
investigation of posttransfusion hemolysis. Anti-M has 
also been implicated in hemolytic disease of the fetus and 
newborn (HDFN). The clinical effects in HDFN as described 
in the literature range from severe HDFN with intrauterine 
death20 to cases where the fetus is unaffected.21 Like anti-K, 
anti-M has been reported to cause suppression of erythroid 
precursors, leading to RBC aplasia and prolonged anemia of 
the newborn.22,23 Hence, anti-M in various clinical settings 
presents differently and demands different management.
In conclusion, anti-M can have varied clinical presentations 
and can interfere during blood grouping and crossmatching. To 
determine the clinical significance of anti-M, elaborate methods 
such as antibody titration, the determination of antibody class, 
and thermal amplitude testing may be necessary. In the case 
of a transfusion requirement for a patient with anti-M, the 
specific clinical setting along with the antibody characteristics 
would determine the course of action to be taken. This report 
also highlights the fact that, in all pretransplant evaluations, a 
minor crossmatch or antibody screening of the donor must be 
performed to ensure that a donor antibody is not missed. Lastly, 
in a stem cell donor, the harvest may require modification to 
avoid any adverse transfusion reaction in the recipient.
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